System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to NG2 / Chondroitin sulfate proteoglycan 4

7.1 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-199-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-199-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-199-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-199-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


NG2 / Chondroitin sulfate proteoglycan 4 is expressed on glial cell populations, but not on normal hepatopoietic cells. It is an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells, where it plays role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes, and supports signaling pathways important for tumor invasion and growth. NG2 also serves as an AML blast tumor marker associated with poor prognosis.


The mouse monoclonal antibody 7.1 recognizes NG2, the melanoma-associated chondroitin sulfate proteoglycan 4 of Mw approximately 220-300 kDa.

Regulatory Status


Human bone marrow stromal cells infected with SV-40

Species Reactivity:

  • Human

Negative Species:


  • Flow Cytometry
  • Immunoprecipitation
  • Western Blotting
  • Immunocytochemistry
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H: Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics. 2010 Jul-Aug;7(4):173-80. [Abstract]
  • Emerenciano M, Renaud G, Sant'Ana M, Barbieri C, Passetti F, Pombo-de-Oliveira MS: Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies. Leuk Res. 2011 Aug;35(8):1001-7. [Abstract]
  • *Girolamo F, Dallatomasina A, Rizzi M, Errede M, Wälchli T, Mucignat MT, Frei K, Roncali L, Perris R, Virgintino D: Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets. PLoS One. 2013 Dec 26;8(12):e84883. [Abstract] [Full Text]
  • *Cattaruzza S, Nicolosi PA, Braghetta P, Pazzaglia L, Benassi MS, Picci P, Lacrima K, Zanocco D, Rizzo E, Stallcup WB, Colombatti A, Perris R: NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. J Mol Cell Biol. 2013 Jun;5(3):176-93. [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    7-1 PE

    Fig. 1. Surface staining of SK-MEL-30 cells with anti-NG2 (7.1) PE (red; blank orange); and SP2 cells (negative, blue; blank green).

    7-1 purified

    Fig. 2. Surface staining of SK-MEL-30 cells with anti-NG2 (7.1) purified; GAM-APC.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy